158 related articles for article (PubMed ID: 38046972)
1. Detection of Axillary Lymph Node Involvement in Early-Stage Breast Cancer: Comparison between Staging
Gupta R; Das J; Sinha S; Agarwal S; Sharma A; Ahmed R; Chanda A; Arun I; Ray S
Indian J Nucl Med; 2023; 38(3):249-254. PubMed ID: 38046972
[TBL] [Abstract][Full Text] [Related]
2. Reliability of predicting low-burden (≤ 2) positive axillary lymph nodes indicating sentinel lymph node biopsy in primary operable breast cancer - a retrospective comparative study with PET/CT and breast MRI.
Sae-Lim C; Wu WP; Chang MC; Lai HW; Chen ST; Chou CT; Liao CY; Huang HI; Chen ST; Chen DR; Hung CL
World J Surg Oncol; 2024 Jan; 22(1):12. PubMed ID: 38183069
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.
Najim O; Dockx Y; Huyghe I; van den Wyngaert T; Papadimitriou K; Tjalma WAA; Huizing MT
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():108-111. PubMed ID: 30145524
[TBL] [Abstract][Full Text] [Related]
4. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
Shao M; Zi J; Wen G
J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
[TBL] [Abstract][Full Text] [Related]
5. Role of fluorine-18-labeled 2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in the evaluation of axillary lymph node involvement in operable breast cancer in comparison with sentinel lymph node biopsy.
Challa VR; Srivastava A; Dhar A; Parshad R; Bal C; Mohan Reddy Gona R; Kumar R; Datta Gupta S; Sharma P
Indian J Nucl Med; 2013 Jul; 28(3):138-43. PubMed ID: 24250021
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
7. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy.
Fehr MK; Hornung R; Varga Z; Burger D; Hess T; Haller U; Fink D; von Schulthess GK; Steinert HC
Breast J; 2004; 10(2):89-93. PubMed ID: 15009033
[TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer.
Lovrics PJ; Chen V; Coates G; Cornacchi SD; Goldsmith CH; Law C; Levine MN; Sanders K; Tandan VR
Ann Surg Oncol; 2004 Sep; 11(9):846-53. PubMed ID: 15313737
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Value of Axillary Ultrasound, MRI, and
Aktaş A; Gürleyik MG; Aydın Aksu S; Aker F; Güngör S
Eur J Breast Health; 2022 Jan; 18(1):37-47. PubMed ID: 35059590
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting the negative predictive value of positron emission tomography/computed tomography for axillary lymph node staging in breast cancer patients.
Kim J; Cho H; Gwak G; Yang K; Kim JY; Shin YJ; Seo YY; Park I
Asian J Surg; 2020 Jan; 43(1):193-200. PubMed ID: 30914155
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer.
Kong EJ; Chun KA; Cho IH; Lee SJ
Nucl Med Mol Imaging; 2010 Sep; 44(3):170-6. PubMed ID: 24899946
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
Heusner TA; Kuemmel S; Hahn S; Koeninger A; Otterbach F; Hamami ME; Kimmig KR; Forsting M; Bockisch A; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1543-50. PubMed ID: 19415270
[TBL] [Abstract][Full Text] [Related]
13. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of sentinel lymph node scintigraphy and 2-[
Reyneke F; Snyman LC; Lawal I; Lengana T; Vorster M; Sathekge M
World J Nucl Med; 2020; 19(3):240-245. PubMed ID: 33354179
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer.
Chae BJ; Bae JS; Kang BJ; Kim SH; Jung SS; Song BJ
Jpn J Clin Oncol; 2009 May; 39(5):284-9. PubMed ID: 19318373
[TBL] [Abstract][Full Text] [Related]
16. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden.
Dabbs DJ; Fung M; Landsittel D; McManus K; Johnson R
Breast J; 2004; 10(2):101-5. PubMed ID: 15009035
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of FDG-PET/CT Scan as Compared to US-Guided FNA in Prediction of Axillary Lymph Node Involvement in Breast Cancer Patients.
Assi HI; Alameh IA; Khoury J; Bou Zerdan M; Akiki V; Charafeddine M; El Saheb GI; Sukhon F; Sbaity E; Baydoun S; Shabb N; Berjawi G; Haidar MB
Front Oncol; 2021; 11():740336. PubMed ID: 34660301
[TBL] [Abstract][Full Text] [Related]
19. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
20. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer.
Kumar R; Zhuang H; Schnall M; Conant E; Damia S; Weinstein S; Chandra P; Czerniecki B; Alavi A
Nucl Med Commun; 2006 Mar; 27(3):231-6. PubMed ID: 16479242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
